New Hope For Hepatitis B Patients?
(Ivanhoe Newswire) -- The World Health Organization (WHO) estimates that two billion people have been infected with the hepatitis B virus (HBV), but a novel drug developed by Gilead Sciences at the Texas Biomedical Research Institute in San Antonio, suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells.
Researchers have found that the immune modulator GS-9620, which targets a receptor on immune cells, reduced both the virus levels and the number of infected liver cells in chimpanzees chronically infected with HBV. Chimpanzees are the only species other than humans that can be infected by HBV. Therefore, the results from this study were critical in moving the drug forward to human clinical trials, which are now in progress.
For more information go to: http://www.gastrojournal.org/article/S0016-5085(13)00169-8/abstract?referrer=http://www.eurekalert.org/pub_releases/2013-04/tbri-nds042513.php
SOURCE: Gastroenterology, April 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.